Maravai LifeSciences Holdings, Inc.
MRVIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMaravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North. The company carries a $1.71B market cap, placing it firmly in the small-cap category. It operates through two segments: TRILINK and CYGNUS.
Market Cap
$1.71B
Beta
0.62
P/E (TTM)
—
P/E (Fwd)
-44.71
EPS (TTM)
$-0.71
EPS (Fwd)
$-0.10
ROE
-41.0%
ROA
-6.6%
Cash
$165.9M
Total Debt
$315.0M
Free CF
-$11.3M
52W Change
106.2%
Annual Financials
Cash vs Debt
Maravai LifeSciences Holdings, Inc. carries $315.0M in total debt against $165.9M in cash reserves — debt is roughly 1.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$11.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -41.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $883.0M (2022) to $185.7M (2025), a 79% decline worth watching.
MRVI's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Maravai LifeSciences Holdings, Inc. and its sector.